Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 20350-15-6 Chemical Structure| 20350-15-6

Structure of Brefeldin A
CAS No.: 20350-15-6

Chemical Structure| 20350-15-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Brefeldin A inhibits protein translocation from the endoplasmic reticulum (ER) to the Golgi apparatus reversibly, can be used to induce autophagy in mammalian cells.

Synonyms: BFA; Decumbin; Bredfeldin A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Brefeldin A

CAS No. :20350-15-6
Formula : C16H24O4
M.W : 280.36
SMILES Code : O[C@@H]1C[C@]2([H])[C@@](/C=C/CCC[C@H](C)OC(/C=C/[C@H]2O)=O)([H])C1
Synonyms :
BFA; Decumbin; Bredfeldin A
MDL No. :MFCD00083258

Safety of Brefeldin A

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • ATPase

    ATPase (HCT 116), IC50:0.2 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Neutrophils 3 μg/ml 4 h BFA treatment reversed the upregulation of surface CD9 and CD47 expression by OTUD1 deficiency upon LPS stimulation, indicating that BFA limits OTUD1-deficient neutrophil secretion by blocking protein transport signaling. PMC10602526
AML12 cells 10 μM 24 h To evaluate the effect of Brefeldin A on XOR release, results showed that Brefeldin A did not alter XOR release PMC10506059
PFHR-9 WT cells 5 μM 12 h Validate the effect of Brefeldin A on inhibiting the secretory pathway of PXDN, results showed that Brefeldin A inhibited the secretion of PXDN. PMC9287737
T24 bladder cancer cells 10-40 nM 24 h To investigate the effects of BFA on ER morphology and cell biomechanics in T24 bladder cancer cells. Results showed that BFA significantly altered the subcellular distribution of the ER and was associated with cytoskeletal rearrangement. PMC10614373
COS7 cells 5 µg/ml 50 min To investigate the effect of BFA treatment on Golgi structure, it was found that BFA treatment causes Golgi dispersion. PMC11451052
HeLa cells 5 µg/ml 1 h To investigate the effect of VPS13B loss on Golgi structure, it was found that the absence of VPS13B delays Golgi recovery. PMC11451052
Porcine intestinal epithelial cells (IPEC-1) 0.1 µM 12 h To investigate the effect of BFA on apoptosis and intestinal barrier function in IPEC-1 cells, results showed that BFA treatment led to increased apoptosis and upregulation of proteins involved in ER stress signaling, while inducing dysfunction in the intestinal epithelial barrier. PMC8669258
J82 0.081 μM 72 h To evaluate the antiproliferative activity of CHNQD-01281 on J82 cells, the results showed that CHNQD-01281 significantly inhibited the proliferation of J82 cells with an IC50 value of 0.081 μM PMC11358582
T24 0.079 μM 72 h To evaluate the antiproliferative activity of CHNQD-01281 on T24 cells, the results showed that CHNQD-01281 significantly inhibited the proliferation of T24 cells with an IC50 value of 0.079 μM PMC11358582
CIK cells 0.5 mg/ml, 2.5 mg/ml, 10 mg/ml 1 h, 12 h, 24 h To investigate the effect of BFA on GCRV replication and infection. Results showed that BFA treatment significantly inhibited GCRV replication and infection, and reduced the number of viral inclusion bodies. PMC9459132
IC21 murine macrophages 5 µg/ml 1 h Brefeldin A was used to block protein secretion from the ER to the Golgi apparatus. The experimental results showed that Brefeldin A treatment did not lead to the accumulation of IL-36γ within the cells, indicating that IL-36γ is not secreted through the conventional secretory pathway. PMC9434278

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Experimental periodontitis model Gingival injection 100 μg/ml Injected on day 1 and day 3 GelMA/BFA significantly suppressed neutrophil recruitment to the gingiva in Otud1─/─mice and effectively ameliorated periodontal inflammation and alveolar bone destruction. PMC10602526
Zebrafish Fam177a1a;fam177a1b DKO;vps13b crispant Immersion 0.8 µg/ml From 6 hpf to 25 hpf To investigate the effect of BFA treatment on zebrafish development, it was found that BFA treatment reduces zebrafish body length. PMC11451052
Nude mice T24 xenograft mouse model Intraperitoneal injection 30 mg/kg Once daily for two weeks To evaluate the antitumor effect of CHNQD-01281 in the T24 xenograft mouse model, the results showed that CHNQD-01281 significantly suppressed tumor growth with a tumor growth inhibition rate of 52.63% PMC11358582

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01742364 - Completed - -
NCT01742364 Tuberculosis Not Applicable Completed - South Africa ... More >> SATVI, University of Cape Town Cape Town, South Africa, 7925 Less <<
NCT03044509 - Recruiting December 2019 Switzerland ... More >> Kantonspital Aarau Recruiting Aarau, Switzerland, 5001 Contact: Sara Bernhard-Stirnemann, Dr med    +41628384192    sara.bernhard@ksa.ch    Kinderspital Basel Recruiting Basel, Switzerland, 4031 Contact: Marina Beaufils-Hugot, PhD    +41617042953    marina.beaufils-hugot@ukbb.ch    Contact: Noemi Meier, Master    +41617042947    noemi.meier@ukbb.ch    Principal Investigator: Nicole Ritz, PD Dr med          Sub-Investigator: Ines Mack, Dr med          Sub-Investigator: Anja Jochmann, Dr med          Sub-Investigator: Daniel Trachsel, PD Dr med          Ospedale Regionale di Bellinzona Recruiting Bellinzona, Switzerland, 6500 Contact: Lisa Kottanattu, Dr med    +41918118538    lisa.kottanattu@eoc.ch    Inselspital Bern Recruiting Bern, Switzerland, 3010 Contact: Andrea Duppenthaler, Dr. med.    +41316329414    andrea.duppenthaler@insel.ch    Hôpital des enfants - HUG Recruiting Genève, Switzerland, 1205 Contact: Anne Mornand, Dr. med.    +41223724579    anne.mornand@hcuge.ch    Sub-Investigator: Marie Rohr, Dr. med.          Kinserspital Luzern Recruiting Luzern, Switzerland, 6016 Contact: Michael Buettcher, Dr med    +41412056657    michael.buettcher@luks.ch    Kinderspital St Gallen Recruiting St. Gallen, Switzerland, 9006 Contact: Jürg Barben, Prof Dr med    +41712437111    juerg.barben@kispisg.ch    Sub-Investigator: Christian Kahlert, Dr med          Kinderklinik Zürich Recruiting Zürich, Switzerland, 8032 Contact: Christoph Berger, Prof Dr med    +41442667840    christoph.berger@kispi.uzh.ch    Sub-Investigator: Christa Relly, Dr med Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.57mL

0.71mL

0.36mL

17.83mL

3.57mL

1.78mL

35.67mL

7.13mL

3.57mL

References

 

Historical Records

Categories